{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-123265","form_type":"8-K","ticker":"OKUR","cik":"0001637715","company_name":"OnKure Therapeutics, Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.061615+00:00","generated_at":"2026-05-30T03:36:16.425440+00:00","sec_items":["4.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Legacy OnKure posts $35.2M net loss in 9mo; auditor switched to KPMG post-merger","bullets":["Net loss of $35.2M for nine months ended Sep 30, 2024, vs $25.9M in prior year.","Cash and equivalents $8.0M as of Sep 30, 2024; accumulated deficit $137.3M.","Ernst & Young dismissed as auditor; KPMG engaged as new independent registered public accounting firm.","Merger with Reneo closed Oct 4, 2024; management expects combined cash to fund operations for at least 12 months.","Convertible notes payable of $6.0M issued in 2024, net of $142k issuance costs."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-123265","json":"https://secwatch.observer/filing/0000950170-24-123265.json","markdown":"https://secwatch.observer/filing/0000950170-24-123265.md","text":"https://secwatch.observer/filing/0000950170-24-123265.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1637715/000095017024123265/0000950170-24-123265-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1637715/000095017024123265/okur-20241107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:36:16.425440+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}